1890 – Novel Influenza Therapeutic

Vaccine development against Influenza is difficult due to viral mutations.Unique target for inhibitor halts viral binding to the cell surface, enabling prevention and treatment of influenza infections. Versatile disease prevention system with applicati…
  • Vaccine development against Influenza is difficult due to viral mutations.
  • Unique target for inhibitor halts viral binding to the cell surface, enabling prevention and treatment of influenza infections.
  • Versatile disease prevention system with applications to medications, masks and clothing, and in medical devices, to prevent the spread of disease.

Abstract:

This technology is a glycomimetic compound that inhibits the binding of multiple strains of Influenza virus, and may inhibit other pathogens, including bacteria, such as BK virus, H. pylori, S. pneumonia, M. pneumonia, E. coli, N. meningitides, and T. gondii. This therapy can be formulated for oral, topical, mucosal, parenteral, or aerosol administration. The glycomimetic can also be implemented into filters, masks, clothing, and/or medical devices.

Website

https://uga.flintbox.com/technologies/0439FA6779EB49CDA83EC38DA6370B2F

Advantages:

-

Potential Applications:

In 2017, the global market related to Influenza was estimated to be over $5 billion, with therapeutics accounting for over $1 billion. Therapeutics have historically targeted viral proteins to prevent virus release from cells. This technology targets the infection cycle at an earlier stage where the virus attempts to attach itself to the cell surface.

Additional Information:

-

Contact Information:

  • Name : "" ""
  • Title :
  • Department :
  • Email: ""
  • Phone : ""
  • Address :